Chronic spontaneous urticaria: therapeutic mechanism of omalizumab and assessment of its clinical efficacy / 中华皮肤科杂志
Chinese Journal of Dermatology
; (12): 652-655, 2019.
Article
en Zh
| WPRIM
| ID: wpr-797851
Biblioteca responsable:
WPRO
ABSTRACT
Chronic spontaneous urticaria (CSU) is characterized by recurrent wheals with severe itching, and greatly affects the life quality of patients. The European guideline on chronic urticaria recommends the anti-IgE monoclonal antibody omalizumab as the only third-line therapy for patients with CSU whose condition can not be controlled by high doses of antihistamines. Although a lot of researches have shown that omalizumab is effective and safe for the treatment of CSU, its therapeutic mechanisms have not yet been fully elucidated. This review summarizes therapeutic mechanisms of omalizumab in the treatment of CSU, and indices for predicting and monitoring its clinical efficacy.
Texto completo:
1
Base de datos:
WPRIM
Tipo de estudio:
Guideline
Idioma:
Zh
Revista:
Chinese Journal of Dermatology
Año:
2019
Tipo del documento:
Article